Skip to content

A New Technology Study on PET/CT Clinical Trials Targeting Fibroblast Activated Proteins in Malignant Tumors

A New Technology Study on PET/CT Clinical Trials Targeting Fibroblast Activated Proteins in Malignant Tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078360
Enrollment
Unknown
Registered
2023-12-06
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

Gold Standard:(1) The pathological results of surgery or biopsy confirm malignant tumors and are positive
(2) If the patient has not undergone surgery or biopsy, imaging follow-up will be conducted. If the lesion increases or increases during follow-up for more than half a year, it will be considered posi
(3) If the patient receives anti-tumor treatment and the lesion shrinks or disappears during follow-up, it is considered positive.
Index test:PET/CT imaging diagnosis of 68Ga-FAPI-04 and 18F-FAPI-04

Sponsors

Hubei Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Voluntarily sign an informed consent form; Suspected malignant tumor patients; Confirmed as a malignant tumor patient;

Exclusion criteria

Exclusion criteria: Critically ill patients, those with respiratory depression, airway obstruction or tissue hypoxia; Drug and/or alcohol abusers, allergic individuals; Those who cannot tolerate and cooperate with the examination; According to the judgment of the researcher, it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;

Secondary

MeasureTime frame
SUVmax;T/NT;

Countries

China

Contacts

Public ContactDasheng Qiu

Hubei Cancer Hospital

hbchpet@163.com+86 153 2728 3223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026